



## 余兆武 助理教授 (Stifen Yu, Assistant Prof.)

- 臺大藥學所博士
- 擁有六年業界經驗
- ✓ **藥物開發**：藥物設計合成、挑選候選藥物，完成製程放大、晶型篩選。
- ✓ **專利&技轉**：從陳基旺教授實驗室技轉到安基生技，完成專利佈局。
- ✓ **臨床試驗**：預計2024年底將有藥物進入Phase I Trial。



## 研究方向

### 表觀遺傳藥物： Histone Deacetylase inhibitors

Quinazolin-2,4-dione based HDAC6 inhibitor for the treatment of NSCLC can display a synergic anticancer effect and reduce PD-L1 expression against lung cancer cells while combining with paclitaxel.  
*J. Med. Chem.* **2019**, 62, 2, 857-874, Cover story

Talk Invitation from Nxxxxxxx Pharma

A highly HDAC6-selective inhibitor acts as a fluorescent probe  
*Org. Biomol. Chem.*, **2018**, 16, 7820-7832, Cover story




### 標的蛋白降解藥物： PROTAC Drug Design

### 化學合成方法： Organometallic synthetic methods

Efficient Microwave-Assisted Pd-Catalyzed Hydroxylation of Aryl Chlorides in the Presence of Carbonate.

*Org. Lett.* **2012**, 14, 14, 3688 - 3691

Most read paper in that issue



國立臺灣大學藥學研究所

GRADUATE INSTITUTES OF PHARMACEUTICAL SCIENCES

